Given that ∼40–50% of BRAFV600E/K melanoma patients fail to respond to BRAF inhibitors (McArthur et al, 2014), there is room for improvement in the biomarker-driven selection of patients beyond simple genetic testing. Here, BRAF is linked to melanoma.